Seeking Alpha

The FDA says J&J's (JNJ -0.3%) bedaquiline for treating a drug-resistant form of...

The FDA says J&J's (JNJ -0.3%) bedaquiline for treating a drug-resistant form of tuberculosis appears to be "safe and well-tolerated," although the highest dose could cause a small change in the heart's rhythm. J&J is seeking accelerated, temporary approval of bedaquiline; an FDA advisory committee is due to review the drug on Wednesday.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|